C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000062032.htmlThe evidence pack includes the HTML, screenshot, summary, and metadata in one ZIP file. For signed-in saves, Kiroku also starts the external RFC 3161 timestamp flow automatically. Downloading the evidence pack is available on Pro. If any asset is still missing, Kiroku prepares it before the download starts.
External timestamp
The evidence pack includes the capture manifest and the RFC 3161 request/response files.
C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces a safety alert for the hepatitis C treatment drug "Sobriard Capsule 100mg" issued by the Japanese Ministry of Health, Labour and Welfare on October 24, 2014. Three domestic deaths related to hyperbilemis that cannot exclude causality with the drug have been reported. The product label was revised with updated precautions, and healthcare providers were notified via a safety letter. Key points include regular monitoring of blood bilirubin levels during treatment, discontinuation if abnormal elevation occurs, continued monitoring after discontinuation, and patient education about warning symptoms requiring immediate medical consultation.
